Researchers have identified a biomarker that may help physicians predict if patients with BRAF-mutant melanomas will respond to drugs designed to target BRAF.
Increased doses of aerobic exercises lasting 50 to 60 minutes were found to be more effective than a standard dose of 30 minutes for managing declines in physical functioning and symptoms such as pain, hot flashes, and fatigue in women undergoing chemotherapy for breast cancer.
Patients with a high body mass index prior to being diagnosed with pancreatic cancer had reduced survival from the disease and were more likely to present with late-stage cancer, according to the results of a recently published study.
Researchers have helped to better define the spectrum of light chain (AL) amyloidosis by identifying that AL amyloidosis patients with myeloma who have more than 10% bone marrow plasma cells or those with hypercalcemia, renal failure, anemia, and lytic bone lesions have a similar prognosis to patients with overt myeloma.
Researchers have identified several risk factors that may help predict which patients with oropharyngeal cancer may require a percutaneous endoscopic gastrostomy tube during chemoradiotherapy, according to a newly published review.
Black race did not adversely affect outcomes after receiving radiotherapy for head and neck squamous cell carcinoma compared with white race, according to the results of a study in which black patients made up the majority of enrolled participants.
The results of a recent study indicated that teenagers with parents who have invasive cancer displayed no greater prevalence of psychosocial problems than did their peers with cancer-free parents.
The two drug combination of cetuximab plus brivanib alaninate worsened quality of life and did not improve overall survival in patients with KRAS wild-type metastatic colorectal cancer.
Adding vorinostat to bortezomib for the treatment of relapsed multiple myeloma resulted in a statistically significant increase in progression-free survival compared with bortezomib alone, according to results of a new study.
No difference in overall survival was seen for surgery with or without FOLFOX4 in patients with initially resectable liver metastases from colorectal cancer, according to the results of a new study.